Penile Cancer Treatment in India and UAE | Complete Patient Guide

• ELIGIBLE PATIENTS:

• Histologically confirmed penile squamous cell carcinoma (or variant histology) at any stage (Tis through T4), including recurrent disease after prior treatment

• Patients with high-grade penile intraepithelial neoplasia (PeIN) unresponsive to topical therapy (imiquimod, 5-fluorouracil) or laser ablation

• Locally advanced disease (T3–T4) requiring neoadjuvant chemotherapy followed by surgery, or definitive chemoradiation

• Patients with clinically palpable inguinal lymphadenopathy (cN1–cN2) requiring inguinal lymph node dissection (ILND)

• Patients with non-palpable nodes but high-risk primary tumor features (T1b or above, high grade) requiring dynamic sentinel node biopsy (DSNB)

• Patients seeking organ-preserving surgery (wide local excision, glansectomy, laser therapy, or Mohs micrographic surgery) for T1a–T2 lesions where a 5 mm clear margin can be achieved

• Patients with metastatic or unresectable disease eligible for systemic chemotherapy (TIP regimen: paclitaxel, ifosfamide, cisplatin) or clinical trials involving anti-PD-1/PD-L1 immunotherapy or EGFR-targeted agents (cetuximab)

• REQUIRED DIAGNOSTIC WORKUP PRIOR TO TREATMENT:

• Incisional or excisional biopsy with formal histopathology, HPV subtyping, and p16 immunohistochemistry

• MRI of the primary tumor with artificial erection technique (intracavernosal prostaglandin E1) for accurate T-staging of corporal involvement

• High-resolution ultrasound of bilateral inguinal regions; CT-guided fine-needle aspiration cytology (FNAC) of suspicious lymph nodes

• FDG-PET/CT scan for patients with palpable nodes (cN1–cN3) or high-risk primary tumors to detect pelvic and distant metastases

• Chest CT and liver ultrasound/CT for systemic staging

• Complete blood count, comprehensive metabolic panel, LFTs, renal function (eGFR critical if cisplatin-based chemotherapy is planned)

• HPV DNA genotyping (tissue-based)

• Psychosexual baseline assessment and fertility counseling for patients of reproductive age

• RELATIVE CONTRAINDICATIONS / CAREFUL PATIENT SELECTION:

• Severe cardiac comorbidity (NYHA Class III–IV) limiting general anesthesia risk — requires pre-operative cardiology clearance and ECHO

• eGFR below 50 mL/min/1.73m² — cisplatin-based regimens require dose modification or substitution with carboplatin

• Active uncontrolled infection at the primary site (requires pre-operative wound optimization)

• Uncontrolled coagulopathy or anticoagulation that cannot be safely bridged

• Distant metastatic disease (M1) is not a contraindication to palliative surgery or systemic therapy but precludes curative-intent radical surgery

ORGAN-SPARING / PENILE-PRESERVING SURGERY (Preferred for T1a–T2, selected T2 lesions):

• Wide Local Excision (WLE): Surgical excision of the primary tumor with a histologically confirmed 5 mm clear margin, used for small glans or prepuce lesions. Intraoperative frozen section margin assessment is mandatory at accredited centers to minimize re-excision rates.

• Laser Ablation (CO2 or Nd:YAG): For Tis and T1a, grade 1–2 lesions where histological confirmation of non-invasive disease is established. Recurrence rates are higher (15–25%) than with WLE but functional outcomes are superior; appropriate patient selection is critical.

• Glansectomy with Split-Thickness Skin Graft (STSG) Reconstruction: The oncological standard for T1b–T2 glans-confined tumors. The entire glans is resected and the neoglans is reconstructed using a split-thickness graft (commonly harvested from the thigh). Functional and cosmetic outcomes are generally excellent; sensation is partially preserved in most patients.

• Mohs Micrographic Surgery: Specialized technique used in select centers for small, well-defined penile SCC where maximal tissue conservation is required; provides real-time margin assessment layer by layer. Available at designated dermatological oncology centers within GAF Healthcare's India and UAE network.

PARTIAL OR TOTAL PENECTOMY (T2 with corporal invasion, T3–T4):

• Partial Penectomy: Resection of the distal penis with a 5–10 mm surgical margin while preserving sufficient shaft length for upright micturition (ideally >3 cm residual length). Perineal urethrostomy is created if residual length is insufficient.

• Total Penectomy with Perineal Urethrostomy: Required for T3 (urethral/corpus cavernosum involvement) or tumors where partial resection cannot achieve clear margins. Radical penectomy may include en-bloc resection of the scrotum and pubic symphysis in T4 disease.

• Phalloplasty / Penile Reconstruction: Radial forearm free flap (RFFF) phalloplasty or anterolateral thigh (ALT) flap reconstruction is offered to selected patients post-total penectomy in specialized reconstructive urology units within the GAF Healthcare network in India and the UAE.

INGUINAL LYMPH NODE MANAGEMENT (Critical for Staging and Cure):

• Dynamic Sentinel Node Biopsy (DSNB): Using technetium-99m nanocolloid and Patent Blue V dye injection into the primary tumor, with gamma-probe-guided sentinel node identification. Recommended for clinically node-negative (cN0) patients with T1b or higher primary tumors. Sensitivity approximately 88–95% in experienced centers.

• Modified Inguinal Lymph Node Dissection (mILND): Performed when DSNB is not available or sentinel node is positive on frozen section. Compared to radical ILND, the modified template reduces wound complications (lymphocele, lymphedema, skin necrosis) while maintaining oncological adequacy for pN1 disease.

• Radical Inguinal Lymph Node Dissection: Required for cN2 (multiple or fixed inguinal nodes) or pathologically confirmed N2 disease. Bilateral dissection is performed even for unilateral palpable disease due to bilateral lymphatic drainage of the penis.

• Pelvic (Ilioinguinal) Lymph Node Dissection: Indicated when 2 or more inguinal nodes are pathologically positive or extra-nodal extension is confirmed, as per EAU guidelines. PET/CT-guided template planning improves yield.

• Video-Endoscopic Inguinal Lymphadenectomy (VEIL): Minimally invasive laparoscopic/robotic-assisted approach to inguinal dissection offering reduced wound morbidity compared to open surgery, available at high-volume robotic urology centers in India (particularly in Chennai, Mumbai, Delhi, and Hyderabad) and in Dubai. Oncological equivalence to open dissection is supported by prospective series.

SYSTEMIC THERAPY:

• Neoadjuvant Chemotherapy (downstaging for cN2–cN3 or unresectable T4 disease): TIP regimen (paclitaxel 175 mg/m², ifosfamide 1200 mg/m² days 1–3, cisplatin 25 mg/m² days 1–3, every 21 days for 4 cycles) — the most evidence-supported first-line regimen based on the MD Anderson series. BMP (bleomycin, methotrexate, cisplatin) is an alternative.

• Adjuvant Chemotherapy: Considered for pN3 disease or extranodal extension following radical lymphadenectomy, though data from randomized trials remain limited.

• Definitive Chemoradiation: For patients unfit for or refusing surgery, concurrent cisplatin-based chemoradiation offers locoregional control rates of 50–60% for T2–T3 disease.

• Radiation Therapy (External Beam / Brachytherapy): HDR brachytherapy (high-dose-rate interstitial brachytherapy) or external beam radiotherapy (EBRT) can achieve organ preservation in T1–T2 glans tumors less than 4 cm in carefully selected patients; 5-year local control approximately 70–80% with brachytherapy.

• Targeted and Immunotherapy (Emerging / Clinical Trial): EGFR overexpression occurs in 40–60% of penile SCCs; cetuximab (anti-EGFR monoclonal antibody) has shown activity in platinum-refractory disease. Anti-PD-1 agents (pembrolizumab, nivolumab) are being evaluated in HPV-positive and high TMB (tumor mutational burden) penile SCC in clinical trials. Biomarker testing (PD-L1 IHC, MSI-H/dMMR, TMB) is recommended for metastatic disease to identify immunotherapy candidates.

PHASE 1 — PRE-TRAVEL CONSULTATION (Weeks 1–2, Remote):

• Patient submits biopsy pathology reports, MRI/CT/PET imaging, and blood work to GAF Healthcare's case management team.

• Senior urological oncologist at the partner hospital reviews records and provides a written second opinion, treatment plan, and itemized cost estimate within 48–72 hours.

• GAF Healthcare assists with e-Medical Visa application (India) or UAE entry arrangements; typical e-Medical Visa processing: 3–5 business days.

• Pre-travel cardiac and anesthetic risk clearance arranged remotely if required.

PHASE 2 — ARRIVAL AND PRE-OPERATIVE WORKUP (Days 1–3 in Country):

• Airport pick-up by dedicated GAF Healthcare coordinator; check-in at pre-arranged hospital-adjacent accommodation for the patient and attendant.

• Repeat or supplementary imaging (MRI with artificial erection if not yet performed; PET/CT if staging is incomplete), inguinal ultrasound with FNAC if clinically indicated.

• Multidisciplinary tumor board (MDT) review of all staging information; finalization of surgical plan (organ-sparing vs. penectomy; unilateral vs. bilateral ILND; neoadjuvant chemotherapy if required).

• Anesthesia pre-assessment, consent process with certified medical interpreter if required.

• If neoadjuvant chemotherapy is planned (cN2–cN3 disease): chemotherapy cycles administered over 9–12 weeks prior to surgery; patient may return home between cycles and travel back for surgical phase.

PHASE 3 — SURGICAL PROCEDURE (Day 3–5):

• Organ-sparing surgery (WLE, glansectomy with STSG): typically 2–4 hours under spinal or general anesthesia; DSNB performed concurrently with gamma-probe and blue dye.

• Partial/total penectomy with bilateral ILND: 4–7 hours; Jackson-Pratt drains placed in inguinal wounds; urethral catheter indwelling for 5–10 days.

• Reconstructive phalloplasty (if planned): may be staged as a second procedure 4–6 weeks after oncological resection, or performed simultaneously at specialized centers.

• Intraoperative frozen section margin assessment performed for all penile-sparing procedures.

PHASE 4 — HOSPITAL RECOVERY (Days 3–14, Depending on Procedure):

• Organ-sparing cases: hospital stay 5–7 days; wound care, catheter management, graft inspection (for STSG cases — graft take assessed at day 5–7).

• Radical penectomy + bilateral ILND: hospital stay 10–14 days; drain removal when output less than 30 mL/24h; inguinal wound monitoring for lymphocele, seroma, or skin necrosis.

• Pathology of resected specimen and lymph nodes reviewed: final pTNM staging, margin status, number of positive nodes, extranodal extension — determines adjuvant therapy decision.

• Physiotherapy for lower limb lymphedema prevention initiated from Day 1 post-ILND.

PHASE 5 — POST-DISCHARGE RECOVERY IN COUNTRY (Weeks 2–6):

• Follow-up wound review at Day 10–14; staple/suture removal.

• Catheter removal and voiding trial (partial penectomy patients typically void satisfactorily within 1–2 weeks).

• Oncology team reviews final pathology; if adjuvant chemotherapy or radiation is recommended, treatment plan communicated to the patient's home oncologist with a full written summary.

• Psychosexual counseling session conducted before departure.

• Fit-to-fly clearance given by surgeon at approximately Week 3 (organ-sparing) to Week 5–6 (radical penectomy + bilateral ILND with no wound complications).

PHASE 6 — LONG-TERM FOLLOW-UP (MONTHS 1–60, REMOTE + IN-PERSON):

• GAF Healthcare's telemedicine platform enables virtual follow-up consultations at 1, 3, 6, 12, 18, 24, 36, 48, and 60 months.

• EAU-recommended surveillance: physical examination + inguinal palpation every 3 months for Years 1–2; every 6 months for Years 3–5; annual thereafter.

• CT chest/abdomen/pelvis at 6, 12, and 24 months for node-positive patients.

• HPV vaccination counseling for eligible patients and sexual partners.